Acc.25: bayer presents new investigational heart failure data and continued portfolio research in chronic kidney disease in type 2 diabetes

Whippany, n.j.--(business wire)--bayer announced today that data from 13 new analyses from across the kerendia® (finerenone) comprehensive clinical trial program will be presented at the american college of cardiology (acc) 74th annual scientific session & expo 2025, taking place in chicago, il, from march 29-31, 2025. ten presentations will feature new data from the pivotal phase iii finearts-hf cardiovascular (cv) outcomes trial, which investigated kerendia for the treatment of adult pati.
ACC Ratings Summary
ACC Quant Ranking